BIBW 2992 (Afatinib) in Head & Neck Cancer
Public ClinicalTrials.gov record NCT00514943. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-label Phase II Study of BIBW 2992 Versus Cetuximab (Erbitux) in Patients With Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of Platinum-containing Therapy With a Cross-over Period for Progressing Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to explore the efficacy of BIBW 2992 compared with cetuximab (Erbitux) in patients with metastatic or recurrent head and neck cancer after failure of platinum-containing therapy. In addition, the trial aims to clarify the influence of EGFR genotype on tumor response to the treatment regimens.
Study identification
- NCT ID
- NCT00514943
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 124 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2007 (Type not available)
- Primary completion
- Mar 2010 (Actual)
- Completion
- Jul 2013 (Actual)
- Last update posted
- Jul 26, 2016
2007 – 2013
United States locations
- U.S. sites
- 18
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1200.28.0010 Boehringer Ingelheim Investigational Site | Stanford | California | — | — |
| 1200.28.0001 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 1200.28.0005 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 1200.28.0011 Boehringer Ingelheim Investigational Site | Harvey | Illinois | — | — |
| 1200.28.0022 Boehringer Ingelheim Investigational Site | Indianapolis | Indiana | — | — |
| 1200.28.0024 Boehringer Ingelheim Investigational Site | Baltimore | Maryland | — | — |
| 1200.28.0012 Boehringer Ingelheim Investigational Site | Ann Arbor | Michigan | — | — |
| 1200.28.0021 Boehringer Ingelheim Investigational Site | Saint Joseph | Michigan | — | — |
| 1200.28.0016 Boehringer Ingelheim Investigational Site | Rochester | Minnesota | — | — |
| 1200.28.0002 Boehringer Ingelheim Investigational Site | Jackson | Mississippi | — | — |
| 1200.28.0006 Boehringer Ingelheim Investigational Site | Omaha | Nebraska | — | — |
| 1200.28.0008 Boehringer Ingelheim Investigational Site | New Hyde Park | New York | — | — |
| 1200.28.0017 Boehringer Ingelheim Investigational Site | Chapel Hill | North Carolina | — | — |
| 1200.28.0004 Boehringer Ingelheim Investigational Site | Winston-Salem | North Carolina | — | — |
| 1200.28.0013 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 1200.28.0007 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1200.28.0009 Boehringer Ingelheim Investigational Site | Madison | Wisconsin | — | — |
| 1200.28.0020 Boehringer Ingelheim Investigational Site | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00514943, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 26, 2016 · Synced Nov 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00514943 live on ClinicalTrials.gov.